Regeneron Pharmaceuticals and Sanofi have announced promising outcomes from the open-label Phase IV DISCOVER trial of ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 most profitable NASDAQ stocks to buy now. On June 9, Regeneron ...

New findings from the EVEREST Phase 4 trial presented at the 2025 EAACI Congress reveal that Dupixent (dupilumab ... 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc.

“EVEREST is the first-ever trial to demonstrate the superiority ... In addition to the currently approved indications, Regeneron and Sanofi are studying dupilumab in a broad range of diseases ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today presented positive results from the EVEREST Phase 4 trial in adults with severe chronic rhinosinusitis with nasal polyps (CRSwNP) and ...

These are the first clinical study results for the drug in a large population of patients with darker skin tones ...

In the trial, Dupixent® (dupilumab) outperformed Xolair® (omalizumab ... Dupixent, which was invented using Regeneron’s proprietary VelocImmune® technology, is a fully human monoclonal ...

In the trial, Dupixent ® (dupilumab) outperformed Xolair ® (omalizumab ... Dupixent, which was invented using Regeneron's proprietary VelocImmune ® technology, is a fully human monoclonal ...

TARRYTOWN, N.Y. and PARIS, June 07, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: REGN) and Sanofi today presented results from the DISCOVER Phase 4, single-arm, open-label trial assessing Dupixent ® (dupilumab) ...

A COPD treatment for former smokers developed by Regeneron Pharmaceuticals and Sanofi failed to meet its primary endpoint in ...